Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

Claire N Harrison,Jyoti Nangalia,Rebecca Boucher,Aimee Jackson,Christina Yap,Jennifer O'Sullivan,Sonia Fox,Isaak Ailts,Amylou C Dueck,Holly L Geyer,Ruben A Mesa,William G Dunn, Eugene Nadezhdin,Natalia Curto-Garcia,Anna Green,Bridget Wilkins,Jason Coppell,John Laurie,Mamta Garg,Joanne Ewing,Steven Knapper,Josephine Crowe,Frederick Chen,Ioannis Koutsavlis,Anna Godfrey,Siamak Arami,Mark Drummond,Jennifer Byrne,Fiona Clark,Carolyn Mead-Harvey,Elizabeth Joanna Baxter,Mary Frances McMullin,Adam J Mead

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

Cited 4|Views53
No score
Abstract
The MAJIC-PV study demonstrates ruxolitinib treatment benefits HC-INT/RES PV patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to our knowledge, that molecular response is linked to EFS, PFS, and OS.
More
Translated text
Key words
polycythemia vera intolerant,hydroxycarbamide
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined